Who Owns Molecular Biology?
By Yarden Katz,
Boston Review
| 10. 28. 2015
Untitled Document
Like much of our society, the American university is increasingly scrutinized through an economic lens. The value of academic research is largely determined by its commercial potential or fundraising capacity. Much has been written about the corrosive effects of this point of view on the humanities, but it has transformed academic science and engineering as well. As Benjamin Ginsberg describes in his book The Fall of the Faculty (2011), universities have been flooded with administrators who view “faculty research mainly as a source of revenue” and “research projects as instruments that generate income.” Yet even the most application-driven universities have always aimed for something beyond enriching their endowment. MIT, for example, declares in its mission statement that it is “committed to generating, disseminating, and preserving knowledge, and to working with others to bring this knowledge to bear on the world’s great challenges,” doing it all “for the betterment of humankind.”
The recent discovery that the CRISPR-Cas system could be used for genome editing illustrates the tension between the corporatization of the university and the pursuit of basic, publicly...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...